- RAPT obtains worldwide rights excluding China -
- Jemincare receives $35 million upfront payment, up to $672.5 million in milestone payments and high single-digit to low-double digit royalties on future sales -
- Jemincare is currently conducting Phase 2 trials in asthma and chronic spontaneous urticaria in China -
- RAPT plans to initiate Phase 2b trial in food allergy next year -
- RAPT to host a conference call at 8:30 a.m. ET -
RAPT will host a webcast conference call today, December 23, 2024 at 8:30 a.m. ET. To join the conference call via phone and participate in the live Q&A session, please pre-register online here to receive a telephone number and unique passcode required to enter the call. The live webcast and audio archive of the presentation may be accessed on the RAPT Therapeutics website at https://investors.rapt.com/events-and-presentations.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.